Amgen Inc on Tuesday said competition for its older drugs sent third-quarter revenue down 3%, but biosimilar sales were strong and the company raised its full-year outlook.
Source:: Reuters – Business News
Newswire
- [ January 30, 2025 ] BigBear.ai (NYSE: BBAI)Awarded Prime IDIQ Contract for U.S. Department of Navy’s SeaPort Next Generation (NxG) Newsmakers
- [ January 30, 2025 ] ScanTech AI Systems (NASDAQ: STAI) Deploys Its Advanced AI-Driven Security Screening Technology to Protect Multiple Nuclear Power Plants Operated by Ontario Power Generation Newsmakers
- [ January 30, 2025 ] Kazia Therapeutics (NASDAQ: KZIA) announces launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancer Newsmakers
- [ January 30, 2025 ] Alpha Modus (NASDAQ: AMOD) Secures 9th AI Patent, Strengthening Leadership in Retail Innovation Newsmakers
- [ January 29, 2025 ] NEWTON GOLF Company (NASDAQ: SPGC) Provides Preliminary Financial Results for Fourth Quarter 2024 and Full Year 2024 Newsmakers
- [ January 28, 2025 ] NanoVibronix (NASDAQ: NAOV)Advances Development of PainShield and UroShield with Completion of NextGen Prototypes Newsmakers
- [ January 27, 2025 ] Nvni Group Limited (NASDAQ: NVNI) reports 2023 FY results: Net Revenue growth of 36%, Adjusted EBITDA up 142% Nvni Group Limited December 26, 2024 5 min read Newsmakers
- [ January 24, 2025 ] Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., (NASDAQ: ELAB) to Present Breakthrough Muscle Preservation Asset at Exclusive UCLA Obesity Symposium Newsmakers
- [ January 23, 2025 ] Banzai (NASDAQ: BNZI) Announces Definitive Agreement to Acquire Act-On Software, Growing TTM Revenue 152% to $44M Newsmakers
- [ January 23, 2025 ] Kopin (NASDAQ: KOPN) to Showcase Newly Advanced Near-to-Eye Microdisplays and Application-Specific Optical Solutions at AR/VR/MR 2025 Newsmakers
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.